Seres Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Seres Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2022-09-30 was $96.72M.
- Seres Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2020-09-30 was $243.75M.
- Seres Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2019-06-30 was $60.53M.
- Seres Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2015-12-31 was $0.00.
- Seres Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2022 was $96.72M.
- Seres Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2020 was $243.75M, a 302.71% increase from fiscal 2019.
- Seres Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2019 was $60.53M.
- Seres Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2015 was $139.27M, a 2785240.00% increase from fiscal 2014.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2022-12-31 | $96.72M 10-K · filed 2025-03-13 | |
| 2022-09-30 | $96.72M 10-Q · filed 2023-11-02 | |
| 2020-12-31 | $243.75M 10-K · filed 2023-03-07 | |
| 2020-09-30 | $243.75M 10-Q · filed 2021-11-10 | |
| 2019-12-31 | $60.53M 10-K · filed 2022-03-01 | |
| 2019-06-30 | $60.53M 10-Q · filed 2020-11-09 | |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $139.27M 10-K · filed 2018-03-08 |
| 2014-12-31 | $5.00K 10-K · filed 2017-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |